SCHEMBL86297

SCHEMBL86297

O=Cc1occc(=O)c1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.64
GAA P10253 1/20 0.64
MAOB P27338 3/20 0.49
MAOA P21397 2/20 0.48
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 2/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KCNA2 P16389 1/20 0.40
KCNA5 P22460 1/20 0.40
KCNA1 Q09470 1/20 0.40
KCNA3 P22001 1/20 0.40
GSTP1 P09211 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28507838 1.00 LMNA (0.64) LMNAGAAMAOBMAOAPOLB
SCHEMBL1793658 0.84 LMNA (0.63) LMNAGAAMAOBMAOAPOLB
SCHEMBL12397421 0.84 LMNA (0.68) LMNAGAAMAOBMAOAPOLB
SCHEMBL1793660 0.84 LMNA (0.63) LMNAGAAMAOBMAOAPOLB
SCHEMBL31513736 0.83 GAA (0.58) LMNAGAAMAOBMAOAPOLB
SCHEMBL31513735 0.83 GAA (0.58) LMNAGAAMAOBMAOAPOLB
SCHEMBL22306971 0.81 LMNA (0.63) LMNAGAAMAOBMAOAPOLB
SCHEMBL81547 0.78 LMNA (1.00) LMNAGAAMAOBMAOAPOLB
SCHEMBL18837889 0.78 GAA (0.52) LMNAGAAMAOBMAOAPOLB
SCHEMBL18837890 0.78 GAA (0.52) LMNAGAAMAOBMAOAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110305091-B Preparation method of Barosavir intermediate compound 江苏理工学院 2021-05-18 CN claimed
US-10442769-B2 Process for the preparation of intermediate of dolutegravir HETERO RESEARCH FOUNDATION (IN) 2019-10-15 US claimed
EP-3016935-B1 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR HETERO RESEARCH FOUNDATION (IN) 2018-09-05 EP claimed
US-20180148412-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR HETERO RESEARCH FOUNDATION (IN) 2018-05-31 US claimed
US-9963430-B2 Process for the preparation of intermediate of dolutegravir HETERO RESEARCH FOUNDATION (IN) 2018-05-08 US claimed
US-20170334858-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR HETERO RESEARCH FOUNDATION (IN) 2017-11-23 US claimed
EP-3016935-A2 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR Hetero Research Foundation (IN) 2016-05-11 EP claimed
WO-2015001572-A2 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR HETERO RESEARCH FOUNDATION (IN) 2015-01-08 WO claimed
CN-119977929-A Pyrone compound and preparation method and application thereof 广东东阳光药业股份有限公司 2025-05-13 CN disclosed
CN-112920202-B Cap-dependent protease inhibitor 北京凯因科技股份有限公司 2024-08-09 CN disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
CN-113286793-B Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines 共结晶制药公司 2024-04-05 CN disclosed
US-20090286987-A1 METALLOPROTEIN INHIBITORS REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO UCSD TECHNOLOGY TRANSFER OFFICE (US) 2009-11-19 US disclosed
US-7579486-B2 Metalloprotein inhibitors REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) 2009-08-25 US disclosed
US-7579486-B2 Metalloprotein inhibitors REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) 2009-08-25 US disclosed
US-20070117848-A1 METALLOPROTEIN INHIBITORS REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 2007-05-24 US disclosed
US-20070117848-A1 METALLOPROTEIN INHIBITORS REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 2007-05-24 US disclosed
WO-2007002109-A2 MULTIDENTATE PYRONE-DERIVED CHELATORS FOR MEDICINAL IMAGING AND CHELATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286987-A1 METALLOPROTEIN INHIBITORS SOD1, ZFX, SOD3 LMNA 3336/4885GAA 156/4885MAOB 31/4885
US-20170334858-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR CYP3A4, DHPS, MVD LMNA 2182/4885GAA 505/4885MAOB 967/4885
US-20180148412-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR CYP3A4, DHPS, MVD LMNA 2182/4885GAA 505/4885MAOB 967/4885
US-20070117848-A1 METALLOPROTEIN INHIBITORS SOD1, ZFX, SOD3 LMNA 3336/4885GAA 156/4885MAOB 31/4885
US-10442769-B2 Process for the preparation of intermediate of dolutegravir CYP3A4, DHPS, MVD LMNA 2182/4885GAA 505/4885MAOB 967/4885
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication PLPBP, EIF2AK2, TYMP LMNA 2998/4885GAA 3634/4885MAOB 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.